19:38 , Apr 27, 2018 |  BC Week In Review  |  Company News

Tonghua gets rights to two insulin products from Adocia

Adocia S.A. (Euronext:ADOC) granted Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) exclusive rights to develop and commercialize BioChaperone Lispro (BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia will receive...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, double-dummy, 3-way crossover, German Phase Ib trial of subcutaneous BioChaperone Combo given before a meal on 3 consecutive days in 36 patients. The trial will compare BioChaperone Combo vs. subcutaneous ...
07:00 , Aug 26, 2016 |  BC Extra  |  Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

BioChaperone insulin: Phase I/II started

Adocia began a double-blind, 3-period crossover Phase I/II trial to compare single doses of HinsBet U100 vs. Humalog and Humulin given immediately prior to ingesting a standardized mixed meal in 36 Type I diabetics. Adocia...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, crossover, German Phase Ib trial to compare 0.8 IU/kg Biochaperone Combo to 0.8 IU/kg Humalog Mix25 and 0.2 IU/kg Humalog insulin lispro plus 0.6 IU/kg Lantus insulin glargine in...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, crossover, German Phase Ib trial to compare BioChaperone Combo to Humalog Mix25 given at the beginning of a standardized mixed meal in about 28 patients. In 2013, Adocia and Eli...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Clinical News

HinsBet BioChaperone insulin: Phase IIa data

A double-blind, crossover Phase IIa trial in 36 Type I diabetics showed that a single 0.2 U/kg dose of HinsBet met the primary endpoint of improving the rate of early insulin exposure vs. a single...
02:08 , Feb 7, 2015 |  BC Extra  |  Clinical News

Adocia climbs on fast-acting insulin data

Adocia S.A. (Euronext:ADOC) rose EUR 9.62 (15%) to EUR 73.40 after the company's HinsBet fast-acting insulin met the primary endpoint of an increase in recombinant human insulin bioavailability during the first hour after dosing compared...
07:00 , Apr 14, 2014 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Final Phase I/II data

Final data from a double-blind, crossover, German Phase I/II trial in 20 Type I diabetics showed that a single 0.8 IU/kg dose of BioChaperone Combo had a faster onset of action, defined as time to...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Preliminary Phase I/II data

Preliminary data from a double-blind, crossover, German Phase I/II trial in 20 Type I diabetics showed that 0.8 IU/kg BioChaperone insulin combo had a 30% faster onset of action, defined as time to >=5% reduction...